These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 33657991)

  • 1. Mitochondrial dysfunction and serum lactate as a biomarker for the progression and disability in MS and its correlation with the radiological findings.
    Esmael A; Talaat M; Egila H; Eltoukhy K
    Neurol Res; 2021 Jul; 43(7):582-590. PubMed ID: 33657991
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum lactate as a novel potential biomarker in multiple sclerosis.
    Amorini AM; Nociti V; Petzold A; Gasperini C; Quartuccio E; Lazzarino G; Di Pietro V; Belli A; Signoretti S; Vagnozzi R; Lazzarino G; Tavazzi B
    Biochim Biophys Acta; 2014 Jul; 1842(7):1137-43. PubMed ID: 24726946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Compounds of Energy Metabolism Impairment Are Related to Disability, Disease Course and Neuroimaging in Multiple Sclerosis.
    Lazzarino G; Amorini AM; Petzold A; Gasperini C; Ruggieri S; Quartuccio ME; Lazzarino G; Di Stasio E; Tavazzi B
    Mol Neurobiol; 2017 Nov; 54(9):7520-7533. PubMed ID: 27826747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and diagnostic features of patients with familial multiple sclerosis.
    Andrijauskis D; Balnyte R; Keturkaite I; Vaitkus A
    Med Hypotheses; 2019 Oct; 131():109310. PubMed ID: 31443766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid evidence of increased extra-mitochondrial glucose metabolism implicates mitochondrial dysfunction in multiple sclerosis disease progression.
    Regenold WT; Phatak P; Makley MJ; Stone RD; Kling MA
    J Neurol Sci; 2008 Dec; 275(1-2):106-12. PubMed ID: 18783801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum NSE level and disability progression in multiple sclerosis.
    Koch MW; George S; Wall W; Wee Yong V; Metz LM
    J Neurol Sci; 2015 Mar; 350(1-2):46-50. PubMed ID: 25686504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability.
    De Stefano N; Narayanan S; Francis GS; Arnaoutelis R; Tartaglia MC; Antel JP; Matthews PM; Arnold DL
    Arch Neurol; 2001 Jan; 58(1):65-70. PubMed ID: 11176938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis.
    Trentini A; Comabella M; Tintoré M; Koel-Simmelink MJ; Killestein J; Roos B; Rovira A; Korth C; Ottis P; Blankenstein MA; Montalban X; Bellini T; Teunissen CE
    J Neurol; 2014 Dec; 261(12):2338-43. PubMed ID: 25228004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS.
    Rudick RA; Lee JC; Nakamura K; Fisher E
    J Neurol Sci; 2009 Jul; 282(1-2):106-11. PubMed ID: 19100997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis.
    Rejdak K; Eikelenboom MJ; Petzold A; Thompson EJ; Stelmasiak Z; Lazeron RH; Barkhof F; Polman CH; Uitdehaag BM; Giovannoni G
    Neurology; 2004 Oct; 63(8):1439-45. PubMed ID: 15505162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal Assessment of Multiple Sclerosis with the Brain-Age Paradigm.
    Cole JH; Raffel J; Friede T; Eshaghi A; Brownlee WJ; Chard D; De Stefano N; Enzinger C; Pirpamer L; Filippi M; Gasperini C; Rocca MA; Rovira A; Ruggieri S; Sastre-Garriga J; Stromillo ML; Uitdehaag BMJ; Vrenken H; Barkhof F; Nicholas R; Ciccarelli O;
    Ann Neurol; 2020 Jul; 88(1):93-105. PubMed ID: 32285956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing the association between disability and biological markers in MS.
    Kalkers NF; Bergers E; Castelijns JA; van Walderveen MA; Bot JC; Adèr HJ; Polman CH; Barkhof F
    Neurology; 2001 Oct; 57(7):1253-8. PubMed ID: 11591845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis.
    Fisniku LK; Brex PA; Altmann DR; Miszkiel KA; Benton CE; Lanyon R; Thompson AJ; Miller DH
    Brain; 2008 Mar; 131(Pt 3):808-17. PubMed ID: 18234696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.
    Axelsson M; Malmeström C; Nilsson S; Haghighi S; Rosengren L; Lycke J
    J Neurol; 2011 May; 258(5):882-8. PubMed ID: 21197541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Magnetic resonance findings in the brain of patients with multiple sclerosis without oligoclonal bands in the cerebrospinal fluid].
    Mesaroc S; Drulović J; Lević Z; Perić V
    Srp Arh Celok Lek; 2003; 131(1-2):31-5. PubMed ID: 14608859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity.
    Högel H; Rissanen E; Barro C; Matilainen M; Nylund M; Kuhle J; Airas L
    Mult Scler; 2020 Feb; 26(2):210-219. PubMed ID: 30570436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum Levels of Biomarkers of Immune Activation and Associations With Neurological Impairment in Relapsing-Remitting Multiple Sclerosis Patients During Remission.
    Witkowska AM; Socha K; Kochanowicz J; Karpińska E; Jakoniuk M; Zujko ME; Wilkiel M; Borawska MH; Mariak Z
    Biol Res Nurs; 2016 Jan; 18(1):113-9. PubMed ID: 25911236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis.
    Benedetti B; Rovaris M; Rocca MA; Caputo D; Zaffaroni M; Capra R; Bertolotto A; Martinelli V; Comi G; Filippi M
    Mult Scler; 2009 Jul; 15(7):789-94. PubMed ID: 19465450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.